Catalog No.
Product Name
Application
Product Information
Citations
-
Immunostimulant
Influenza A NP (383-391) (HLA-B27) is a peptide sequence that functions as an immunostimulant by targeting CD4+ T helper cells. This epitope is known to enhance the activation and proliferation of CD8+ cytotoxic T lymphocytes (CTLs), thereby promoting robust immune responses. It is applicable in research related to breast cancer and other areas of immunotherapy, facilitating the exploration of T cell-mediated responses in cancer models. -
Cholesterol-conjugated Oseltamivir Carboxylat Prodrug
OC-C2-Cholesterol is a cholesterol-conjugated prodrug of Oseltamivir carboxylate, designed to enhance oral bioavailability. This compound exhibits protective effects against influenza virus infections by providing prolonged circulation of Oseltamivir carboxylate compared to traditional formulations. OC-C2-Cholesterol serves as a valuable tool in influenza research, contributing to the understanding of antiviral efficacy and metabolism. -
CEN Inhibitor
Cap-dependent endonuclease-IN-23 is a selective inhibitor of cap-dependent endonuclease (CEN), effectively blocking its activity. This compound demonstrates significant antiviral properties by inhibiting the replication of influenza A virus. Cap-dependent endonuclease-IN-23 is intended for research applications focused on understanding and combating influenza virus infections. -
Anti-influenza Agent
ATV2301 is an orally active anti-influenza agent targeting key viral components, including polymerase acid protein (PA), nuclear protein (NP), and RNA-dependent RNA polymerase (RdRp). It exhibits potent antiviral activity, demonstrated by an EC50 of 1.88 nM against H1N1 and 4.77 nM against H3N2. ATV2301 is suitable for research applications involving the study of influenza virus replication and the development of antiviral therapeutics. -
Hemagglutinin Fragment
Hemagglutinin (48-68) is a peptide fragment derived from the hemagglutinin protein of the influenza virus. This fragment has been shown to effectively induce the proliferation of peptide-specific T-cell clones, making it valuable for research applications related to T-cell responses and adaptive immunity. It serves as a useful tool for studying the immunogenic properties of influenza virus and may aid in vaccine development and immune profiling assays. -
Anti-influenza Agent
Nepasaikosaponin K is an anti-influenza agent that exhibits potent antiviral activity against the influenza virus A/WSN/33 (H1N1). It demonstrates an EC50 value of 17.91 μM in 239T-Gluc cells, indicating its effectiveness in inhibiting viral replication. This compound is suitable for research applications focused on the development of antiviral therapies and understanding influenza virus biology. -
Anti-Oxidant
Methyl brevifolincarboxylate is a potent anti-oxidant compound that exhibits significant inhibitory effects on influenza virus PB2 cap-binding. This reagent also demonstrates the ability to inhibit platelet aggregation, modulate lipid metabolism, and reduce inflammation. Its diverse biological activities make it a valuable tool for research in virology, cardiovascular studies, and inflammatory response. -
Influenza Viru
CEF1 is an epitope derived from the Influenza Matrix Protein M1 (58-66), targeting the matrix protein of the influenza A virus. This peptide is essential for studies focusing on immune response and vaccine development against influenza infections. Its utilization in research can enhance understanding of viral pathogenesis and facilitate the development of therapeutic strategies. -
Gastroprotective Compound
Saussureamine C is a gastroprotective compound that demonstrates significant protective effects against acidified ethanol-induced gastric mucosal lesions in experimental rat models. Additionally, it exhibits inhibitory activity against the H274Y and N294S mutants of the influenza virus, making it a valuable tool in research related to viral infections. Saussureamine C is isolated from the dried roots of Saussurea lappa Clarke, providing a natural source for investigation into its pharmacological properties. -
Antiviral Agent
Antiviral Agent 65 selectively targets the influenza H1N1 virus, demonstrating an effective half-maximal inhibitory concentration (EC50) of 7 μg/mL. This compound exhibits significant antiviral activity, making it a valuable tool for research focused on influenza virus inhibition and therapeutic development. Its efficacy supports its use in investigations aimed at understanding antiviral mechanisms and potential treatment strategies against H1N1 infection. -
Influenza Virus Inhibitor
Viral polymerase-IN-1 hydrochloride is a potent inhibitor of influenza A and B viruses, demonstrating inhibitory concentration (IC90) values ranging between 11.4 and 15.9 μM. This compound also exhibits activity against SARS-CoV-2, effectively suppressing viral infection. The primary mechanism of action involves the disruption of viral RNA replication and transcription within host cells, making it a valuable reagent for research into antiviral therapies and viral pathogenesis. -
Antiviral
Oseltamivir-fructosyl is an antiviral compound that primarily targets influenza viruses. It demonstrates significant antiviral activity, providing an effective means to inhibit viral replication. Additionally, Oseltamivir-fructosyl exhibits inhibitory effects against various bacteria, including Streptococcus spp. and Serratia marcescens, making it a valuable reagent for research focused on viral infections and antimicrobial resistance. -
PAN Inhibitor
Influenza virus-IN-6 is a potent inhibitor of the N-terminal domain of the polymerase acidic protein subunit (PAN) endonuclease, exhibiting an IC50 value of 0.20 μM. This compound demonstrates significant antiviral activity against influenza viruses, making it a valuable tool for research applications focused on influenza virus replication and therapeutics. Its inhibitory effects on PAN endonuclease provide insights into the molecular mechanisms of influenza pathogenesis and potential treatment strategies. -
Neuraminidase Inhibitor
Drechslerine A is a neuraminidase inhibitor with an IC50 value of 0.79 μM. This terpene, isolated from the endophytic fungus Cochliobolus, exhibits significant antiviral activity. Drechsilerine A is utilized in research related to the influenza virus, making it a valuable tool for studying viral pathogenesis and therapeutic interventions. -
Anti-Influenza Agent/PDF Inhibitor
FR198248 is an anti-influenza agent that acts as a peptide deformylase (PDF) inhibitor. Isolated from Aspergillus flavipes, FR198248 demonstrates potent inhibition of the PDF enzyme in Staphylococcus aureus, with an IC50 value of 3.6 µM. This compound is suitable for use in antiviral and antibacterial research applications, allowing for further exploration of its therapeutic potential against viral and bacterial pathogens. -
Neuraminidase Inhibitor
Neuraminidase-IN-3 is a potent inhibitor of influenza neuraminidase, exhibiting IC50 values of 0.73 nM, 0.26 nM, and 0.63 nM against H1N1, H5N1, and H5N8 neuraminidases, respectively. This compound is critical for research focused on antiviral drug development and studying the mechanisms of influenza virus infection and resistance. Its high potency makes it a valuable tool for elucidating neuraminidase functions in viral pathogenesis and therapeutics. -
Antiviral Agent
Selenazofurin is an antiviral agent that targets influenza A and B viruses, exhibiting effective inhibition of viral replication. In addition, it demonstrates potent antiviral activity against Measles, Para-3, Mumps, Vaccinia Virus, and HSV-2, with effective doses (ED50) ranging from 1.3 μg/ml to 8.0 μg/ml. This compound is a valuable tool for research into viral pathogenesis and therapeutic interventions for viral infections. -
Influenza Virus Inhibitor
D715-2441 is an influenza virus RNA polymerase inhibitor with an IC50 range of 1.7-4.4 μM. This compound demonstrates broad-spectrum antiviral activity against various influenza A strains. D715-2441 serves as a valuable tool for research pertaining to seasonal influenza and the study of influenza virus dynamics. -
Antiviral Agent
Antiviral Agent 78, an antiviral compound, demonstrates significant efficacy against various viral pathogens. It exhibits IC50 values of 11.22 μM against 2019-nCoV, 78.54 μM against Ebola virus replicon, and 71.49 μM against avian influenza virus A/Guangzhou/99. This compound is suitable for research applications focusing on viral infections and has the potential to aid in the development of antiviral therapeutics. -
Influenza A Virus Inhibitor
M2WJ332 is a potent inhibitor of the M2 proton channel in the Influenza A virus, specifically targeting the M2S31N mutant variant. With an IC50 of 16 μM, M2WJ332 effectively prevents plaque formation in Influenza A virus carrying the M2S31N mutation. This compound is suitable for research applications focused on understanding and combating Influenza A virus infections. -
Influenza Viru Inhibitor
Laninamivir TFA is a long-acting neuraminidase inhibitor that effectively targets influenza A and B viruses. This antiviral compound exhibits both inhibitory and prophylactic activity, making it a valuable tool for influenza research. Administered via nasal inhalation, Laninamivir TFA demonstrates promising safety and efficacy profiles in the inhibition of viral replication, supporting its application in studies of influenza virus dynamics and treatment strategies. -
Influenza A Inhibitor
Influenza A virus-IN-17 is a selective inhibitor targeting Influenza A viruses, demonstrating effective inhibition with EC90 values of 3.5 μM for H3N2 and 2.6 μM for H1N1. This compound effectively disrupts the cap-snatching polymerase activity, as indicated by an EC90 of 2.1 μM against U2-PB2 chimeric mRNA. Influenza A virus-IN-17 is suitable for research in antiviral drug development and understanding Influenza A virus mechanisms. -
H1N1 Hemagglutinin Inhibitor
RO5464466 is a potent inhibitor of hemagglutinin (HA) in H1N1 influenza viruses. It effectively inhibits HA-mediated hemolysis of chicken erythrocytes, demonstrating an IC50 value of 0.29 μM. This compound is valuable for research applications focused on influenza virus entry mechanisms and the development of antiviral strategies. -
Anti-influenza Agent
PPQ-581 is an anti-influenza agent that targets viral protein synthesis, exhibiting an EC50 of 1 μM for the prevention of virus-induced cytopathic effects. This compound effectively inhibits the nuclear export of ribonucleoproteins (RNP) and prevents cytoplasmic RNP aggregation. PPQ-581 is valuable for research applications focused on understanding the mechanisms of influenza virus replication and the development of potential therapeutic strategies. -
Anti-influenza Agent
Influenza virus-IN-10 is a dual-target anti-influenza agent that inhibits both the polymerase acidic protein (PAC) with a binding affinity of 8.9 μM and the nucleoprotein (NP) with a binding affinity of 52.5 μM. Exhibiting an EC50 of 1.64 μM against the influenza A virus (H1N1, A/WSN/33), this compound demonstrates broad-spectrum antiviral activity against various strains, including influenza B and multiple subtypes of influenza A. It is a valuable tool for research into influenza virus mechanisms and therapeutic interventions. -
Antiviral Agent
Oseltamivir impurity-1 is a carboxylic acid derivative and an impurity of the antiviral agent Oseltamivir. This compound exhibits antiviral activity against various strains of the influenza virus, making it significant for research in antiviral drug development and quality control processes. Its relevance in biological assays allows for improved understanding of antiviral mechanisms and the evaluation of drug purity. -
Beraprost Sodium Analogue
GP-1681 is an analogue of Beraprost Sodium, primarily targeting the modulation of prostaglandin pathways. This compound has demonstrated potential biological activity in the research of influenza A H5N1 infection. Its ability to influence inflammatory responses may provide insights into therapeutic strategies for antiviral interventions. Researchers can utilize GP-1681 to explore its effects on viral pathogenesis and host response in influenza studies. -
PIV-3 Inhibitor
Caesalmin E is a natural cassane furanoditerpene that acts as a potent inhibitor of the Parainfluenza virus type 3 (PIV-3). Its antiviral properties make it a valuable compound for research focused on combating viral infections, specifically in studies targeting PIV-3-related pathologies. This compound may be utilized in investigations of viral replication mechanisms and as a potential therapeutic agent against respiratory infections. -
Influenza Virus Fusion Inhibitor
BMS-199945 is an influenza virus fusion inhibitor that targets the viral fusion process. It demonstrates significant inhibitory activity with IC50 values of 0.57 μM against influenza A/WSN/33 virus-induced hemolysis in chicken red blood cells and approximately 1 μM in the trypsin protection assay. This reagent is applicable for research into antiviral therapies and the mechanisms of influenza virus pathogenesis. -
Antiviral Agent
Kistamicin B is an antiviral agent that exhibits potent activity against influenza virus and herpes simplex virus. The compound demonstrates an ID50 of 1.8 μg/mL against influenza virus in MDCK cells and 30 μg/mL against herpes simplex virus. Its efficacy makes it a valuable tool for research in virology and the development of antiviral therapies. -
NA Inhibitor
ent-Oseltamivir, the enantiomer of Oseltamivir, serves as a neuraminidase (NA) inhibitor targeting influenza virus. Its primary biological activity involves inhibiting viral replication, making it a valuable tool for studying influenza virus infections. Research applications include evaluating antiviral efficacy and resistance mechanisms, contributing to the development of effective therapeutic strategies against influenza. -
Matriptase Inhibitor Intermediate
Sodium 3-iodobenzenesulfonate serves as an intermediate in the synthesis of Matriptase inhibitors, specifically those derived from 3-amidinophenylalanine. This reagent is valuable for research applications involving the inhibition of Matriptase and has been implicated in studies related to the H9N2 influenza virus. Its utility in chemical research makes it an important compound for exploring therapeutic avenues targeting Matriptase and associated viral infections. -
Furin Inhibitor
Furin-IN-3 is a potent and selective inhibitor of the proprotein convertase furin, exhibiting a Ki of 12.4 nM. Additionally, it demonstrates a Ki of 278 nM for PC7. This compound has been shown to exert significant antiviral activity against the furin-dependent H7N7 influenza A virus strain SC35M by inhibiting the cleavage and activation of the viral hemagglutinin (HA), thereby preventing viral membrane fusion with host cells and inhibiting viral replication. Furin-IN-3 is a valuable tool for research into viral infections, particularly those related to influenza. -
Anti-Influenza A Virus Agent
IAV-IN-3 is a potent inhibitor of the influenza A virus (IAV) polymerase, exhibiting an IC50 of 0.045 μM. This compound shows strong antiviral activity with an EC50 of 0.134 μM, while demonstrating minimal cytotoxicity (CC50 = 15.35 μM in MDCK cells). IAV-IN-3 is ideal for research applications focused on the mechanisms of antiviral action and the development of therapeutic strategies against IAV infections. -
Anti-Influenza Agent
Anti-Influenza agent 6 (compound 19b) primarily targets influenza viruses, demonstrating potent inhibitory activity against A/WSN/33/H1N1 with an EC50 of 0.015 μM. Additionally, it exhibits substantial efficacy against influenza B virus strains Yamagata/16/88 (EC50 = 0.073 μM) and Victotis/2/87 (EC50 = 0.067 μM). This compound serves as a valuable tool for research applications focused on virology and the development of antiviral therapies. -
Influenza Inhibitor
6-Epi-albassitriol is a potent influenza inhibitor derived from Aspergillus sp. FH-A 6357. It effectively disrupts cholesterol synthesis, achieving an inhibition rate of 40% at a concentration of 10 nM in HepG2 cells. Additionally, 6-Epi-albassitriol demonstrates significant antiviral activity against both influenza A virus and parainfluenza virus, with a minimum inhibitory concentration (MIC) ranging from 44.4 to 133.3 µg/mL, making it a valuable compound for research in antiviral therapeutics. -
IAV Inhibitor
IAV replication-IN-1 is a potent inhibitor of influenza A virus (IAV) replication. This compound effectively reduces the upregulation of inflammatory factors and apoptosis associated with IAV infection, providing potential protective effects against lung injury induced by the virus. It is suitable for research applications focused on viral pathogenesis, inflammation, and therapeutic interventions in respiratory diseases. -
Anti-virus agent
Platyphylloside is an anti-viral agent derived from the bark of Alnus japonica. It demonstrates significant activity against the H9N2 avian influenza virus, making it a valuable compound for influenza research. This reagent can aid in the development of therapeutic strategies and enhance understanding of viral mechanisms. -
Antiviral Agent
Noformicin is an antiviral agent that exhibits inhibitory effects against mumps virus and Newcastle disease virus in chicken embryos. Additionally, Noformicin has been shown to prolong survival in mice infected with swine influenza A (PR8) and influenza B (Lee) viruses. This compound serves as a valuable tool for studying viral pathogenesis and developing antiviral therapies. -
Influenza A Inhibitor
Pimodivir hydrochloride hemihydrate (VX-787) is an orally bioavailable inhibitor targeting the influenza A virus polymerase by specifically interfering with the PB2 subunit. This compound demonstrates significant antiviral activity against various strains of the influenza A virus, making it a valuable tool for research in virology and antiviral drug development. Its mechanism of action paves the way for studying the dynamics of viral replication and the efficacy of potential therapeutic interventions. -
Influenza Virus Inhibitor
M090 is a potent inhibitor of hemagglutinin, specifically targeting the influenza A virus. It effectively inhibits multiple strains of influenza, demonstrating an EC50 in the micromolar range. This compound is essential for research applications involving antiviral drug development and the study of influenza virus pathogenesis. -
Anti-H1N1 Swine Flu Compound
Methyl isoferulate, also known as Isoferulic acid methyl ester, targets the influenza M2 proton channel, exhibiting significant anti-H1N1 swine flu activity. This compound is valuable in research focused on antiviral strategies against influenza viruses, particularly in elucidating mechanisms of viral entry and replication. Its ability to inhibit the M2 channel highlights its potential as a lead compound for therapeutic development against swine flu. -
Hemagglutinin Inhibitor
F0045(S) is an effective inhibitor of influenza hemagglutinin, demonstrating a KD value of 6.1 µM. This compound is utilized in biological research to investigate its protective effects against influenza virus infections in human cells, making it a valuable tool for antiviral studies and the development of therapeutic strategies. -
Influenza Virus M1 Fragment
CEF3 is a peptide corresponding to amino acids 13-21 of the influenza A virus M1 protein, which serves as a crucial component in the viral life cycle. The matrix protein (M1) is known for its multifunctional properties, contributing to viral assembly, budding, and overall stability. This reagent is valuable for research applications focused on understanding influenza virus biology and developing antiviral strategies. -
Influenza Virus NP Fragment
CEF4 is a peptide corresponding to amino acids 342-351 of the nucleocapsid protein of the influenza A virus. It serves as a crucial tool for studying the structure and function of viral components and assessing immune responses. This reagent is particularly useful in research applications related to influenza virus pathogenesis and vaccine development. -
Influenza Virus Inhibitor
CEF6 is a 9-amino acid peptide derived from residues 418-426 of the nucleocapsid protein of influenza A virus (H1N1). It functions as an inhibitor of influenza virus, demonstrating key antiviral activity through interference with the viral life cycle. This peptide is valuable for research applications focused on studying viral replication mechanisms and the development of antiviral therapeutics targeting influenza infections. -
Influenza Virus Inhibitor
Sodium copper chlorophyllin B is a sodium-copper complex of chlorophyll with demonstrated antiviral activity against the Influenza virus, exhibiting IC50 values between 50 to 100 μM. It also shows potential activity against HIV. This compound is primarily utilized in research applications aimed at understanding antiviral mechanisms and developing therapeutic strategies for viral infections. -
Antimicrobial Agent
PD 131628 is an antimicrobial agent and a potent active metabolite of PD 131112. It exhibits two- to four-fold greater activity than Ciprofloxacin, effectively inhibiting all strains of Staphylococcus aureus and Streptococcus pneumoniae. PD 131628 demonstrates strong efficacy against Neisseria spp., Haemophilus influenzae, and Moraxella catarrhalis, with MIC90 values ranging from 0.004 to 0.008 mg/L, making it a valuable tool for antimicrobial research applications. -
Influenza Viru Inhibitor
(E/Z)-RA-0002034 is an inhibitor targeting the protease activity of the Chikungunya virus (CHIKV) nsP2, with an IC50 value of 58 nM. This compound covalently modifies the catalytic cysteine residue in a site-specific manner, leading to the inhibition of viral replication. It serves as a valuable tool for studying CHIKV biology and developing antiviral therapies against Chikungunya virus infections. -
Influenza Virus Inhibitor
Glabranine is a flavonoid compound recognized for its inhibitory effects against the influenza virus. Isolated from Tephrosia species, it demonstrates significant interaction with the soluble ectodomain of the dengue virus type 2 (DENV2) E protein, suggesting potential applications in antiviral research. This compound serves as a valuable tool for investigating the mechanisms of viral inhibition and offers insights into therapeutic strategies against influenza and related viral infections.
